Video from last weeks OXY Talks where Vironova's CEO and founder Mohammed Homman shares his entrepreneurial journey with Susanna Balsvik and Emma Vallin from OXY Group. Who together from different views and experiences explore the challenges and...
Mohammed Homman CEO at Vironova AB awarded the "Top Talens Creator Award" by SwedenBIO
We are delighted and honored for the recognition we got at SwedenBIO´s Executive Dinner and BIO-Gala, where our CEO Mohammed Homman received the “Top Talent Creator Award” on behalf of Vironova. An award given to those creating talent for the future!
Annual General Meeting 2021 - Vironova AB
Shareholders of Vironova AB (publ), 556678-1463, are hereby summoned to our annual general meeting which will be held on June 30, 2021.
New collaboration between National Physical Laboratory (NPL) and Vironova to empower the UK life science industry
NPL’s Biometrology laboratory will further increase their electron microscopy capabilities by hosting Vironova’s MiniTEM system through a new partnership between the organizations.
AI research for automated microscopy imaging and processing
Together with leading microscopy image processing researchers at Uppsala University, Vironova has recently published a new peer reviewed research article in the area of microscopy imaging and processing. The article investigates if and how some of...
New collaboration with SwedenBIO to develop the life science industry
Vironova’s Director Human Resources, Ann Fredriksson, will be one of a handful members of a new task force put together by SwedenBIO. The cross-organizational group will focus on finding solutions to current human resource challenges in the Nordic...
Vironova Medical AB in development of SARS-CoV-2 antiviral drugs
Vironova Medical AB, a spin off from Vironova AB, have developed an antiviral drug candidate against SARS-CoV-2. A novel class of antiviral drugs against covid-19/SARS-CoV-2, first evaluated in vitro against SARS-CoV-2 virus at the University of...
Vironova is part of the MAD-CoV 2 project
The SARS-CoV-2 pandemic has had a significant negative impact on the world’s public health and the global economy since its outbreak in the beginning of 2020. From this has the international MAD-CoV 2 project emerged, trying to provide an increased...
Vironova in strategic collaboration with a top-tier consultancy
Stockholm, 1st of December 2020. A message from our CEO, Mohammed Homman. I am very pleased to announce a new strategic partnership between Vironova and a top-tier management consultancy1, focusing on accelerating Vironova’s growth and valuation.